Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.6207 USD | -1.87% | -7.36% | -16.75% |
Apr. 04 | North American Morning Briefing : Focus Turns to -2- | DJ |
Apr. 04 | Traws Pharma, Inc. Announces Chief Executive Office Changes | CI |
Strengths
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The opinion of analysts covering the stock has improved over the past four months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-16.75% | 13.34M | - | ||
+1.51% | 42.59B | B | ||
+8.57% | 40.65B | B- | ||
+49.22% | 40.57B | A | ||
-12.36% | 26.77B | C | ||
+8.92% | 24.81B | B- | ||
-25.13% | 18.17B | B | ||
+29.17% | 12.05B | C+ | ||
-3.12% | 11.7B | C+ | ||
+6.35% | 11.1B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- TRAW Stock
- Ratings Traws Pharma, Inc.